Back to Search Start Over

Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19

Authors :
Aitor Uribarri
Gonzalo Cabezón Villalba
Pablo Elpidio García-Granja
J. Alberto San Román
Carlos Veras
Jordi Candela
V. Ramos
Marta Pérez-Poza
Itziar Gómez
Teba González Ferrero
Óscar Otero García
Ana Revilla
Pablo José Antúnez Muiños
Carla Eugenia Cacho Antonio
José Francisco Gil
Álvaro Aparisi
Diego López Otero
Gino Rojas
Carlos Cerda Dueñas
Pablo Catalá
Javier López-Pais
José Ramón González-Juanatey
Ignacio J. Amat-Santos
Marta Marcos
Source :
Cardiol J
Publication Year :
2020

Abstract

BACKGROUND: Cardiovascular risk factors and usage of cardiovascular medication are prevalent among coronavirus disease 2019 (COVID-19) patients. Little is known about the cardiovascular implications of COVID-19. The goal herein, was to evaluate the prognostic impact of having heart disease (HD) and taking cardiovascular medications in a population diagnosed of COVID-19 who required hospitalization. Also, we studied the development of cardiovascular events during hospitalization. METHODS: Consecutive patients with definitive diagnosis of COVID-19 made by a positive real time- -polymerase chain reaction of nasopharyngeal swabs who were admitted to the hospital from March 15 to April 14 were included in a retrospective registry. The association of HD with mortality and with mortality or respiratory failure were the primary and secondary objectives, respectively. RESULTS: A total of 859 patients were included in the present analysis. Cardiovascular risk factors were related to death, particularly diabetes mellitus (hazard ratio in the multivariate analysis: 1.810 [1.159- -2.827], p = 0.009). A total of 113 (13.1%) patients had HD. The presence of HD identified a group of patients with higher mortality (35.4% vs. 18.2%, p < 0.001) but HD was not independently related to prognosis; renin-angiotensin-aldosterone system inhibitors, calcium channel blockers, diuretics and beta-blockers did not worsen prognosis. Statins were independently associated with decreased mortality (0.551 [0.329-0.921], p = 0.023). Cardiovascular events during hospitalization identified a group of patients with poor outcome (mortality 31.8% vs. 19.3% without cardiovascular events, p = 0.007). CONCLUSIONS: The presence of HD is related to higher mortality. Cardiovascular medications taken before admission are not harmful, statins being protective. The development of cardiovascular events during the course of the disease is related to poor outcome.

Details

ISSN :
1898018X
Volume :
28
Issue :
3
Database :
OpenAIRE
Journal :
Cardiology journal
Accession number :
edsair.doi.dedup.....ea0df2db2d9211139d843bd958e4b8cd